Expert panel recommendations: practical clinical applications for initiating and monitoring Resmetirom in patients with MASH/NASH and moderate to noncirrhotic …
M Noureddin, MR Charlton, SA Harrison… - Clinical …, 2024 - Elsevier
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in four people
in the United States and western Europe, with an important proportion developing metabolic …
in the United States and western Europe, with an important proportion developing metabolic …
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated …
MA Tincopa, R Loomba - Seminars in Liver Disease, 2024 - thieme-connect.com
Risk of disease progression and clinical outcomes in metabolic dysfunction-associated
steatotic liver disease (MASLD) is associated with fibrosis stage and presence of “at-risk …
steatotic liver disease (MASLD) is associated with fibrosis stage and presence of “at-risk …
Prevalence of at‐risk MASH, M et ALD and alcohol‐associated steatotic liver disease in the general population
CV Schneider, KM Schneider, A Raptis… - Alimentary …, 2024 - Wiley Online Library
Background The prevalence of at‐risk metabolic dysfunction‐associated steatohepatitis (at‐
risk MASH) has not been systematically assessed. Aim To delineate the prevalence of at …
risk MASH) has not been systematically assessed. Aim To delineate the prevalence of at …
[HTML][HTML] Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach
Background & Aim An unbiased genome-first approach can expand the molecular
understanding of specific genes in disease-agnostic biobanks for deeper phenotyping …
understanding of specific genes in disease-agnostic biobanks for deeper phenotyping …
Dysfunctional VLDL metabolism in MASLD
Lipidomics has unveiled the intricate human lipidome, emphasizing the extensive diversity
within lipid classes in mammalian tissues critical for cellular functions. This diversity poses a …
within lipid classes in mammalian tissues critical for cellular functions. This diversity poses a …
Degree of discordance between FIB-4 and transient elastography: an application of current guidelines on general population cohort
M Chang, D Chang, S Kodali, SA Harrison… - Clinical …, 2024 - Elsevier
Background & Aims In the American Gastroenterological Association/American Association
for the Study of Liver Diseases (AGA/AASLD) Clinical Care Pathway, Fibrosis-4 index (FIB …
for the Study of Liver Diseases (AGA/AASLD) Clinical Care Pathway, Fibrosis-4 index (FIB …
[HTML][HTML] A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease
Q Huang, SF Qadri, H Bian, X Yi, C Lin, X Yang… - Journal of …, 2024 - Elsevier
Background & Aims Metabolic dysfunction-associated steatohepatitis (MASH) is associated
with a> 10-fold increase in liver-related mortality. However, biomarkers predicting both …
with a> 10-fold increase in liver-related mortality. However, biomarkers predicting both …
Associations of traditional healthy lifestyle and sleep quality with metabolic dysfunction-associated fatty liver disease: two population-based studies
J Yang, Q Zhang, W Zhao, B Ye, S Li, Z Zhang… - Nutrition & …, 2024 - nature.com
Aims To examine whether an extended lifestyle metrics incorporating sleep quality improves
risk stratification for metabolic dysfunction-associated fatty liver disease (MAFLD), at-risk …
risk stratification for metabolic dysfunction-associated fatty liver disease (MAFLD), at-risk …
[HTML][HTML] Metabolomics at the cutting edge of risk prediction of MASLD
EY Tan, MD Muthiah, AJ Sanyal - Cell Reports Medicine, 2024 - cell.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major public health
threat globally. Management of patients afflicted with MASLD and research in this domain …
threat globally. Management of patients afflicted with MASLD and research in this domain …
Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach
T Mouskeftara, G Kalopitas, T Liapikos… - International Journal of …, 2024 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD), nowadays the most prevalent chronic liver disease
in Western countries, is characterized by a variable phenotype ranging from steatosis to …
in Western countries, is characterized by a variable phenotype ranging from steatosis to …